

# Prasanth Reddy Nyalapatla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7683183/publications.pdf>

Version: 2024-02-01

18  
papers

520  
citations

840776

11  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

851  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro). <i>Journal of Biological Chemistry</i> , 2015, 290, 19403-19422.	3.4	134
2	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4267-4278.	6.4	64
3	Zinc Catalyzed and Mediated Asymmetric Propargylation of Trifluoromethyl Ketones with a Propargyl Boronate. <i>Journal of Organic Chemistry</i> , 2013, 78, 3592-3615.	3.2	47
4	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented nM to pM potency. <i>ELife</i> , 2017, 6, .	6.0	44
5	Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein-Ligand X-ray Studies. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6792-6802.	6.4	42
6	Design of Highly Potent, Dual-Acting and Central Nervous System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants. <i>ChemMedChem</i> , 2018, 13, 803-815.	3.2	36
7	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4561-4577.	6.4	31
8	X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5072-5077.	2.2	19
9	Enantioselective Total Synthesis of (+)-Amphirionin-4. <i>Organic Letters</i> , 2016, 18, 2296-2299.	4.6	16
10	Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5114-5127.	3.0	16
11	Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. <i>Scientific Reports</i> , 2020, 10, 10664.	3.3	13
12	Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	12
13	A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2625-2635.	3.2	10
14	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 11607-11621.	2.8	10
15	Total syntheses of both enantiomers of amphirionin 4: A chemoenzymatic based strategy for functionalized tetrahydrofurans. <i>Tetrahedron</i> , 2017, 73, 1820-1830.	1.9	10
16	A New Synthesis of Gefitinib. <i>Synlett</i> , 2019, 30, 471-476.	1.8	6
17	Fluorescent Probes for Monitoring Serine Ubiquitination. <i>Biochemistry</i> , 2020, 59, 1309-1313.	2.5	6
18	Co(II)-salen catalyzed stereoselective cyclopropanation of fluorinated styrenes. <i>Chirality</i> , 2019, 31, 1014-1027.	2.6	4